Origenis extends
Research Alliance with Alcon
to develop novel ophthalmic compounds
Munich, Germany, June
2006 - Origenis GmbH
today announced that it has extended the research alliance with
Alcon Research, Ltd. to develop small molecule drugs against
important ophthalmic targets for two years. The alliance combines
Origenis' compound design and synthesis capabilities with Alcon's
applied biology expertise, screening capabilities and development
expertise.
Origenis has developed a unique process to design and synthesize
novel molecules acting against different targets, which targets
will be chosen by Alcon. Origenis will apply its technology
platform MOREsystem® to deliver pre-clinical candidates with
indication optimized profiles for certain Alcon targets.
Under the terms of the agreement, Alcon will retain the rights to
any products for ophthalmic and nasal applications and Origenis
will retain certain rights to all other uses of drug candidates
discovered during the alliance.
Alcon will make research payments to Origenis through a series of
development milestones and royalties on sales.
Dr. Michael Thormann, Managing Director at Origenis said:
"This
extension validates the strength of our technology platform, which
allows the design, synthesis, and characterization of novel
molecules acting against given targets in combination with giving
these molecules indication-specific advantageous properties.
Origenis' approach combines lead finding and lead optimization in
one step, thus, reducing attrition and shorting time to
market."
Dr. Marty Wax, Vice President Ophthalmology Discovery Research at
Alcon added: "We have been
impressed with Origenis' capabilities and performance since the
commencement of our relationship and we look forward to continuing
our successful relationship in the future."
-ends-
Notes
Origenis GmbH
(www.origenis.de) is a privately owned Germany-based
company offering creative services for drug design, synthesis, and
characterisation driven by a patented technology platform. This
unique, fast, and highly integrated platform - MOREsystem® - has
been developed and validated by an interdisciplinary team of
scientists over several years and is now applied for origenis'
partners. MOREsystem® enables the directed target and indication
optimised exploitation of billions of novel compounds through a
proprietary multiparametric optimisation
process.
For further
information please contact:
Dr. Michael Thormann, Managing
Director
Tel: +49 (0)89 7801 676 0
michael.thormann@origenis.de
| |
Attachments: